eMed, a Miami, FL-based digital healthcare company, has raised $200 million in a funding round led by AON Consulting.
The round also saw participation from Tom Brady (CWO), Jeff Aronin, Ara Cohen, Antonio Gracias, Joe Lonsdale, R.J. Melman, Tom Ricketts, and Linda Yaccarino (CEO).
The company is valued at over $2 Billion valuation.
The company plans to use the funds to improve its platform and support a new model that helps employers reduce healthcare costs.
The Series A funding confirms eMed’s strong growth and positions it as a leading platform for population health at scale. The company will use the funds to improve its AI platform and support a new model aimed at reducing healthcare costs for employers.
GLP-1 medications are one of the most in-demand workplace benefits, but only about 20% of companies currently offer them. eMed is working to make these treatments more accessible to employees.
Read More:Scalvy Raises $13.9M in Series A Funding
eMed provides a clinically managed GLP-1 program designed specifically for employers. These treatments are highly effective, but their success depends on patients staying consistent with the therapy.
With over 90% member adherence—more than double the industry average—eMed delivers strong results, including an average weight loss of 21 pounds and health improvements for 99% of users within six months.
“I believe eMed’s AI platform, along with its strong team and partners, creates a powerful formula for success. That’s why I’ve decided to invest both my time as Founding Chief Wellness Officer and my own capital in the company,” said Tom Brady.
About eMed
Founded in 2020, by Dr. Patrice Harris, eMed is a digital healthcare company focused on three key areas: GLP-1 weight management programs for employers, at home “test-to-treat” services with virtual support for conditions like COVID 19 and flu, and an AI platform designed to help employers manage healthcare costs and improve patient adherence.
Read More:Helix Earth Raises $12M in Seed 2 Funding
